These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 29036248

  • 1. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
    Bagel J, Nelson E, Keegan BR.
    J Drugs Dermatol; 2017 Oct 01; 16(10):957-962. PubMed ID: 29036248
    [Abstract] [Full Text] [Related]

  • 2. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M, Walsh S, Shear N.
    J Cutan Med Surg; 2016 Jul 01; 20(4):313-6. PubMed ID: 26848145
    [Abstract] [Full Text] [Related]

  • 3. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis.
    Calzavara-Pinton PG, Sala R, Arisi M, Rossi MT, Venturini M, Ortel B.
    Br J Dermatol; 2013 Jul 01; 169(1):130-6. PubMed ID: 23834117
    [Abstract] [Full Text] [Related]

  • 4. A randomized, 'head-to-head' pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients.
    Park KK, Wu JJ, Koo J.
    J Eur Acad Dermatol Venereol; 2013 Jul 01; 27(7):899-906. PubMed ID: 22702846
    [Abstract] [Full Text] [Related]

  • 5. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
    Bagel J, Samad AS, Stolshek BS, Aras GA, Chung JB, Kricorian G, Kircik LH.
    J Drugs Dermatol; 2018 Oct 01; 17(10):1078-1082. PubMed ID: 30365588
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, Goncalves J, Levi E, Callis Duffin K.
    J Drugs Dermatol; 2017 Aug 01; 16(8):801-808. PubMed ID: 28809995
    [Abstract] [Full Text] [Related]

  • 7. Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.
    Khemis A, Fontas E, Moulin S, Montaudié H, Lacour JP, Passeron T.
    J Invest Dermatol; 2020 Aug 01; 140(8):1533-1537.e2. PubMed ID: 32004567
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K, Gooderham M, Bewley A, Green L, Soung J, Petric R, Marcsisin J, Cirulli J, Chen R, Piguet V.
    J Eur Acad Dermatol Venereol; 2018 Mar 01; 32(3):397-402. PubMed ID: 29220542
    [Abstract] [Full Text] [Related]

  • 9. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D.
    J Eur Acad Dermatol Venereol; 2018 Jul 01; 32(7):1173-1179. PubMed ID: 29388335
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, Levi E, Duffin KC.
    J Drugs Dermatol; 2018 Feb 01; 17(2):221-228. PubMed ID: 29462231
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
    Tzaneva S, Geroldinger A, Trattner H, Tanew A.
    Br J Dermatol; 2018 Mar 01; 178(3):682-688. PubMed ID: 29114862
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J.
    J Eur Acad Dermatol Venereol; 2017 Mar 01; 31(3):507-517. PubMed ID: 27768242
    [Abstract] [Full Text] [Related]

  • 15. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis.
    De Simone C, D'Agostino M, Capizzi R, Capponi A, Venier A, Caldarola G.
    Eur J Dermatol; 2011 Mar 01; 21(4):568-72. PubMed ID: 21697032
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
    Ighani A, Georgakopoulos JR, Zhou LL, Walsh S, Shear N, Yeung J.
    J Cutan Med Surg; 2018 Mar 01; 22(3):290-296. PubMed ID: 29373924
    [Abstract] [Full Text] [Related]

  • 18. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
    Ortonne JP, Khemis A, Koo JY, Choi J.
    J Eur Acad Dermatol Venereol; 2005 Sep 01; 19(5):556-63. PubMed ID: 16164708
    [Abstract] [Full Text] [Related]

  • 19. Systematic review of UV-based therapy for psoriasis.
    Almutawa F, Alnomair N, Wang Y, Hamzavi I, Lim HW.
    Am J Clin Dermatol; 2013 Apr 01; 14(2):87-109. PubMed ID: 23572293
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.